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● Staphylococcus aureus bacteremia (SAB) increases rates of morbidity and
mortality and requires rapid and appropriate antimicrobial selection to
resolve symptoms and remove the infection
● Treatment of choice is a β-lactam or vancomycin for MSSA and MRSA
bacteremia, respectively
● Uncomplicated SAB:
○ Short-course treatment with systemic antibiotics for 14 days
○ Long-course treatment for 28 days is preferred to eliminate potential for
complications and relapse
● Complicated SAB:
○ Long-course treatment is recommended at ≥ 4 weeks
● To assess appropriate treatment of SAB (by antibiotic selection and 
duration of therapy) and to determine if targeted therapy, relapse or SAB-
related readmission, length of stay, and mortality rates were affected by 
the presence of an Infectious Disease (ID) consultation
○ Primary Outcome
 Percentage of patients treated appropriately for SAB (by antibiotic 
selection and duration of therapy)
○ Secondary Outcomes
 Antimicrobial stewardship interventions
 Timing of ID consults
 Difference in outcomes due to presence of an ID consult
• Appropriate targeted therapy
• Recurrence or SAB-related readmission, length of stay, and 
mortality rate
● Complete data collection and analysis at all Wellstar facilities pending
● At Wellstar North Fulton hospital, primary outcome of appropriate treatment of SAB
based on appropriate antibiotic selection and appropriate duration of therapy was
met in 71% (5 out of 7) patients
○ However, one patient expired prior to the completion of therapy. Primary 
outcome was met in 83% (5 out of 6) patients if excluding that patient.
○ One patient who qualified for long-course treatment received only a short course
● Vancomycin was the most common agent used for MRSA bacteremia. Alternatives
included daptomycin, ceftaroline, and linezolid based on concurrent infections
● Vancomycin was started initially for the MSSA patients but later changed to
ceftriaxone or nafcillin upon confirmation of MSSA. Some patients also received
piperacillin/tazobactam or meropenem for MSSA for concurrent Gram-negative and
anaerobic coverage
● Difference in outcomes due to the presence of ID consultation was difficult to
assess in this small subset of patients.
○ Upon completion of data collection/assessment at all facilities, these outcomes 
will be evaluated
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RESULTS DISCUSSION
CONCLUSION
● S.aureus bacteremia was treated appropriately in majority of patients when
reviewing selection of antibiotics and duration of treatment. Practitioners will be
educated to re-emphasize longer treatment durations for patients with diabetes,
evidence of immunosuppression, metastatic infection, endocarditis, prosthetic or
intravascular devices, and lack of improvement within 72 hours of antibiotic
treatment.
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METHODS
● A retrospective chart review was conducted by Wellstar hospital system in
the greater Atlanta area from January 1 to June 30 in 2017
● Patients were identified from microbiology reports of positive blood cultures
with S.aureus
● Information collected includes baseline characteristics, selection and
duration of antibiotic therapy, presence of ID consultations, and follow up
reports of complications post therapy
● Patient Population
○ Inclusion criteria
▪ ≥ 18 yrs of age
▪ S. aureus isolated from one or more blood cultures
○ Exclusion criteria
▪ Antibiotic susceptibilities unavailable prior to death
▪ Care withdrawn prior to therapy being selected or targeted therapy 
completed
● Statistical analysis: descriptive analysis 
Primary Outcome: 
 Percentage of patients treated appropriately for SAB based on: 
o Antibiotic selection: 7 out of 7 patients
o Duration of therapy: 5 out of 7 patients
 Eight patients at Wellstar North Fulton hospital presented with S. aureus bacteremia during January, 2017 to June,
2017
 One patient was excluded as care was withdrawn prior to the completion of targeted therapy
Secondary Outcomes: 
 Antimicrobial Stewardship Interventions: 5 out of 7 patients had documented interventions that were accepted
 Timing of ID Consultations: 4 out of 7 patients had an ID consult placed on the first day. ID was consulted on days 2, 
3, or 5 for the remaining patients
Primary Outcome: Appropriate 
Selection of Antibiotics Alone
Appropriate Inappropriate
Primary Outcome: Appropriate 
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